What can you tell us about the mechanism of action of brincidofovir as a nucleotide analog lipid-conjugate?

Can you walk us through the evidence of Brincidofovir’s antiviral activity against the 5 families of double-stranded DNA viruses?

What procedures would the company have to follow in making this countermeasure drug available to patients in advance of an outbreak, if approved?

What potential does brincidofovir have in adenovirus and cytomegalovirus infections?

What are the implications in regards to biodefense, the Strategic National Stockpile and global public health?

The company filed the drug as a medical countermeasure against smallpox under the FDA’s Animal Efficacy Rule. Can you tell us more about this pathway to approval?

Chimerix used rabbits or mice that were inoculated with rabbitpox or ectromelia virus, respectively, to determine the survival benefit of BCV. How accurately do you think the results would translate to human efficacy, considering that the antiviral target of BCV (viral DNA polymerase) in both models is approximately 98% identical to variola virus ?

In its 2 studies, animals that received BCV, regardless of time post-infection, demonstrated a survival advantage. What are your top-level insights, after looking at the post infection survival plots?